Fundraising FoxIecure
3 known investors
Find your way into Iecure
Sign up to see every warm intro you have to Iecure
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Iecure team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
iECURE is a clinical-stage biotechnology company developing in vivo genome editing therapies that insert a functional copy of a gene into a patient's genome to treat rare, life-threatening genetic diseases in children. Its initial focus is on neurometabolic and urea cycle disorders, including ornithine transcarbamylase (OTC) deficiency.
Founders & leadership
JM
James M. WilsonScientific Founder
AM
Alex MonteithChief Business Officer
GM
Gabriel M. CohnChief Medical OfficerGabriel M. Cohn is Chief Medical Officer at iECURE, a clinical-stage biotech company developing in vivo genome editing therapies for rare genetic diseases. A physician with board certification in Obstetrics, Gynecology, and Clinical Genetics, an MBA, and prior experience in translational medicine and rare disease development across gene therapy and enzyme replacement therapy programs.
Investors · 3
OrbiMed✓ confirmed by IecureNew York · $1M – $75M
How we know: OrbiMed's portfolio page · the company's own site · the VCSheet dataset · Not right? Tell us
Versant Ventures✓ confirmed by IecureSan Francisco · $250K – $5M
How we know: the company's own site · a partner's Signal profile · Not right? Tell us
Frequently asked questions
- What does Iecure do?
- iECURE is a clinical-stage biotechnology company developing in vivo genome editing therapies that insert a functional copy of a gene into a patient's genome to treat rare, life-threatening genetic diseases in children. Its initial focus is on neurometabolic and urea cycle disorders, including ornithine transcarbamylase (OTC) deficiency.
- Who founded Iecure?
- Iecure was founded by James M. Wilson.
- Who are Iecure's investors?
- Iecure's investors include OrbiMed, LYFE Capital, Versant Ventures.